Article

KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.

Department of Cell Biology, Faculty of Medicine, Fukuoka University 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
Anticancer research (impact factor: 1.73). 07/2011; 31(7):2535-9. pp.2535-9
Source: PubMed

ABSTRACT We previously investigated the mRNA expression of colorectal cancer cell lines via a microarray analysis and found several genes that were significantly up-regulated by oncogenic KRAS under serum-starved conditions. Of these genes, we focused on ribonucleotide reductase M2 (RRM2), which was reported to be associated with DNA synthesis.
Cell proliferation and colony formation assays were performed using HCT116 cells transfected with lentiviral RRM2-shRNAs.
Under serum-starved conditions, the expression level of RRM2 protein increased in HCT116 cells compared to HKe3 cells (HCT116 cells with a disruption in oncogenic KRAS), and the re-expression of KRAS in HKe3 cells induced the expression of RRM2. Both the cell proliferation under serum-depleted conditions and the anchorage-independent growth were impaired by the reduction of RRM2 protein expression.
RRM2 represents a novel therapeutic target, thus highlighting the potential utility of RRM2 inhibitors in colorectal cancer with oncogenic KRAS.

0 0
 · 
0 Bookmarks
 · 
69 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

anchorage-independent growth
 
cell proliferation
 
colony formation assays
 
colorectal cancer
 
colorectal cancer cell lines
 
DNA synthesis
 
HCT116 cells transfected
 
lentiviral RRM2-shRNAs
 
mRNA expression
 
novel therapeutic target
 
oncogenic KRAS
 
potential utility
 
re-expression
 
ribonucleotide reductase M2
 
RRM2
 
RRM2 inhibitors
 
RRM2 protein
 
RRM2 protein expression
 
serum-depleted conditions